Patients with Nijmegen Breakage Syndrome (NBS) have a high risk to develop malignant diseases, most frequently B-cell lymphomas. It has been demonstrated that this chromosomal breakage syndrome results from mutations in the NBS1 gene that cause either a loss of full-length protein expression or expression of a variant protein. A large proportion of the known NBS patients are of Slavic origin who carry a major founder mutation 657del5 in exon 6 of the NBS1 gene. The prevalence of this mutation in Slav populations is reported to be high, possibly contributing to higher cancer risk in these populations. Therefore, if mutations in NBS1 are associated with higher risk of developing lymphoid cancers it would be most likely to be observed in these populations. A multiplex assay for four of the most frequent NBS1 mutations was designed and a series of 119 lymphoma patients from Slavic origin as well as 177 healthy controls were tested. One of the patients was a heterozygote carrier of the ACAAA deletion mutation in exon 6 (1/119). No mutation was observed in the control group, despite the reported high frequency (1/177). The power of this study was 30% to detect a relative risk of 2.0.
Introduction
Nijmegen Breakage Syndrome (NBS) is an autosomal recessive chromosomal instability disorder similar to the ataxia telangiectasia (AT) resulting in microcephaly, growth retardation, and immunodeficiency. Malignancies of lymphoid origin at young age present with defects in the cell cycle check points and increased sensitivity to ionising radiation. 1 -3 Moderately elevated cancer risk for heterozygote carriers of mutations in the ATM gene has been reported for leukemias, non-Hodgkin's lymphomas and breast cancer. 4 The gene (NBS1) of a size of 56 kb is localised on 8q21.3, and codes for a gene product termed Nbs1, p95, or nibrin of 754 amino acids. 5 The protein is an essential part of a multifunctional complex involved in DNA double-strand break repair and response to radiation. Interactions of nibrin with BRCA1 and ATM/ATR have been shown upon DNA damage. 6 Nibrin forms a complex with Mre11, and Rad50 in vivo, 7 which has suggested functions in both homologous recombination and nonhomologous endjoining and also a role in telomere maintenance. Nibrin is itself essential for some catalytic activities of this complex such as ATP-dependent partial unwinding of a DNA duplex 8 and the ATM-dependent activation (phosphorylation) of Chk2 upon gamma radiation. 9 The abrogation of this activation leads to entry into mitosis immediately after radiation suggesting that checkpoint defects may result from inability to activate Chk2. However, evidence for Nbs1-dependent phosphorylation of CHK2 has been obtained from some cell lines, 9 but not in others, where repair defects rather than a check point arrest have been proposed as a mechanism to increased radiosensitivity. 10 Nibrin has been shown to be essential in the radiation-induced phosphorylation of Mre11 (human meiotic recombination 11), by recruiting specific kinases.
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Initially, the 657del5 allele was suggested to lead to a premature stop and a truncated protein giving a surprisingly mild phenotype, given that the mouse NBS1 knockout leads to early embryonic lethality. 12 Recently, an alternative translation was shown to lead to a variant, possibly partly functional NBS1 protein. 13 Using screening techniques designed to detect carriers of the common mutations Varon et al found an unexpectedly high carrier frequency of the 657del5, which may contribute to cancer frequency in the studied Slav populations. 14 To verify that we designed a study for the simultaneous screening for the mutations in NBS1 in the following positions: exon 6, 657 delACAAA, 698 delAACA, exon 7, 835delCAGA, 842 insT, and exon 10, 1142 delC. 
Materials and methods

Subjects
DNA extraction
Genomic DNA was isolated from peripheral lymphocytes by the phenol/chloroform extraction method followed by ethanol precipitation according to standard protocols.
Mutation screening
A single tube, multiplex PCR analysis of the major known mutations in NBS1 was developed using the three primer pairs given in Table 1. DNA (50 -100 ng) were mixed with 30 pmol of each primer, 0.2 mM of each dNTP, 1.2 mM MgCl 2 , PCR Buffer II from Perkin-Elmer (MgCl 2 -free), and 0.75 U Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA) in a final volume of 30 ml. After initial denaturation at 931C for 30 s, amplification was accomplished using a protocol with 20 cycles including 30 s at 941C, 30 s at 62 -421C with a decrement of 11 in each cycle, and 30 s at 721C, followed by 10 cycles with annealing temperature 491C in each cycle, with a final extension of 10 min at 721C in a PE9600 cycler. The fragment lengths of the PCR products were 136 bp for exon 6, 140 bp for exon 7, and 160 bp for exon 10 of NBS1 (Figure 1 ). Primers were labelled with FAM for exon 6, HEX for exon 7 and TET for exon 10. After completion of the multiplex PCR reaction with labelled primers, the mix was analysed by a single run of capillary electrophoresis on ABI PRISMt310. Running conditions at voltage 15 kV, 5 s injection time and a length of run of 24 min were set for optimal detection of the polymorphic alleles. 
Results
A single tube, multiplex PCR-based method for screening of the major known mutations in NBS1 has been developed ( Figure 1 ). Using this method we screened for mutated NBS1 alleles in 119 lymphoma patients of Czech origin and 177 controls. In addition, the studied exons (exons 6, 7, and 10) have been amplified separately and sequenced to verify the results in 11 randomly chosen patients and 13 Figure 1 Multiplex PCR reaction was analysed by a single run of capillary electrophoresis on ABI PRISMt310. The fragment lengths of the PCR products, 134 bp for exon 6, 140 bp for exon 7, and 160 bp for exon 10 of NBS1 for the homozygous wt are given relative to the internal standard. Primers were labelled with FAM for exon 6 (two blue peaks for a heterozygous deletion of 5 bp), HEX for exon 7 (two black peaks for a heterozygous deletion of 4 bp) and TET for exon 10 (two green peaks for a heterozygous deletion of 1 bp). Running conditions at voltage 15 kV, 5 s injection time and a length of run of 24 min were set for optimal detection of the polymorphic alleles. NBS1 in lymphoma patients of Slavic origin P Soucek et al controls. One of the patients was a heterozygote carrier of the ACAAA deletion mutation in exon 6 (1/119) ( Figure 2) . No mutation was observed in the control group, despite the reported high frequency (1/177) 14 of the 657del5 mutation in Slavic populations. The present study does not therefore report an increased relative risk for lymphoma patients carrying the Slavic mutation although it was observed in one of the patients (n ¼ 119) and in none of the controls (n ¼ 177). The probability of finding no mutations, if the true probability in the population is P, can be calculated as follows (using the formula for the binomial distribution):
In our example n ¼ 119 and P ¼ 0.005 (or 1/177) the probability of observing one mutation would be 0.995 119 ¼ 0.55. If the true probability was twice that observed in the control population (P ¼ 2/177) then it is 0.99 119 ¼ 0.30 (P ¼ 0.01), that is, our study had a 30% probability to detect an RR ¼ 2.
Discussion
Both Hodgkin's and non-Hodgkin's lymphomas constitute a diverse group of malignancies with respect to histology, clinical presentation and disease progression. Genetic polymorphisms in xenobiotic metabolising enzymes of the cytochrome P450 and glutathione S-transferase superfamilies may contribute to disease risk. 15 The possible involvement of mutations in the NBS1 gene in the pathogenesis of lymphoid diseases is suggested by the fact that this is the most common form of malignancy suffered by NBS patients. 1 Furthermore, mutations in the gene were found in some cases (14.9%) of childhood acute lymphoblastic leukemia 15 but not large deletions in the NBS1 area on chromosome 8q. 17 Since at least one of the known variants, 657del5 in exon 6, was found in 1/177 healthy individuals of Slav origin, 14 we believed that it is feasible to expect a higher frequency of carriers of this mutation in lymphoma patients of the same population. Our results did not confirm this hypothesis in the studied patient groups. A larger set of both cases and controls is under investigation. However, the rapid and convenient screening technique that we introduce in this study could be used for larger population screening or for patient groups with increased radiosensitivity and abnormal response to radiation treatment.
